Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 11/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12696301 | 0.86 | CYP3A4 (0.44) | HTR2CDRD2DRD3 | |
| SCHEMBL23104752 | 0.86 | HTR2C (0.45) | HTR2CDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL28961463 | 0.85 | CYP3A4 (0.43) | HTR2CDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29591748 | 0.85 | CYP3A4 (0.43) | HTR2CDRD2DRD3 | |
| SCHEMBL4203489 | 0.80 | HTR2C (0.47) | HTR2CHTR2ACHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL15282909 | 0.78 | HTR2C (0.46) | HTR2CHTR2ACHRM4CHRM5CHRM1 | |
| SCHEMBL3373891 | 0.77 | ADRA2A (0.52) | HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL3162510 | 0.77 | ADRA2A (0.47) | HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL31587209 | 0.77 | ADRA2A (0.47) | HTR2CHTR2ADRD2DRD3 | |
| SCHEMBL29522031 | 0.77 | ADRA2A (0.52) | HTR2CHTR2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | claimed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | claimed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | claimed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-1899330-B9 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| EP-1899330-B1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
| WO-2008009125-A9 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | NPS ALLELIX CORP (CA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | HTR2C 2345/4885HTR2A 3269/4885CHRM4 207/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | HTR2C 2195/4885HTR2A 3030/4885CHRM4 164/4885 |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885CHRM4 107/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | HTR2C 2195/4885HTR2A 3030/4885CHRM4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.